Cost of cardiovascular diseases and renal complications in people with type 2 diabetes mellitus in the Kingdom of Saudi Arabia: A retrospective analysis of claims database.
Ahmed Hamden Al-Jedai, Hajer Yousef Almudaiheem, Dema Abdulrahman Alissa, Hadi Saeed Al-Enazy, Ghazwa B Korayem, Ahlam Alghamdi, Shabab Alghamdi
Author Information
Ahmed Hamden Al-Jedai: Therapeutic Affairs, Ministry of Health, Riyadh, Saudi Arabia. ORCID
Hajer Yousef Almudaiheem: Therapeutic Affairs Deputyship, Ministry of Health, Riyadh, Saudi Arabia.
Dema Abdulrahman Alissa: Therapeutic Affairs Deputyship, Ministry of Health, Riyadh, Saudi Arabia. ORCID
Hadi Saeed Al-Enazy: Department of Family Medicine, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.
Ghazwa B Korayem: Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia. ORCID
Ahlam Alghamdi: Princess Nourah University, Riyadh, Saudi Arabia.
Shabab Alghamdi: Council of Cooperative Health Insurance, Riyadh, Saudi Arabia.
BACKGROUND: The burden of macro- and microvascular complications in patients with Type 2 diabetes mellitus (T2DM) is substantial in Middle East countries. The current study assessed the healthcare resource utilization (HCRU) and costs related to cardiovascular and renal complications among patients with T2DM. METHODOLOGY: This non-interventional, longitudinal, retrospective, cohort study collected secondary data from three insurance claims databases across Kingdom of Saudi Arabia (KSA) of patients diagnosed with T2DM. The study included adult patients aged ≥18 years diagnosed with first cardiovascular disease (CVD) during index time period and at least one T2DM claim anytime during the study time period. The primary analyses were conducted per database, stratified by three cohorts; patients with at least one claim every six months during the 1-year pre-index and 1-year post-index period (cohort 1), patients with at least one claim every six months during the 1-year pre-index, and two years post-index period (cohort 2) and patients with at least one claim every six months during the 1-year pre-index and 3-year post-index period (cohort 3). For each Payer database, demographics, CVD subgroups, HCRU, and costs were analysed. Descriptive statistics were used to analyse the data. RESULTS: The study sample comprised of 72-78% male and 22-28% female T2DM patients with CVD and renal complications. Patients in the age group of 35-65 years or above contributed to the significant disease burden. Nearly 68 to 80% of T2DM patients developed one CVD event, and 19 to 31% of patients developed multiple CVD events during the follow-up period. For most patients with comorbid CVD and renal disease, the average HCRU cost for post‑index periods was higher compared to 1-year pre-index period across the different visit types and activities. CONCLUSION: The study findings elucidates the need for early initiation of therapies that would reduce the long-term cardiovascular and renal outcomes and the associated costs in patients with T2DM.
